NASDAQ:LVTX LAVA Therapeutics (LVTX) Stock Price, News & Analysis $2.04 +0.04 (+2.01%) (As of 10/28/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends About LAVA Therapeutics Stock (NASDAQ:LVTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get LAVA Therapeutics alerts:Sign Up Key Stats Today's Range$1.95▼$2.0650-Day Range$1.57▼$2.0452-Week Range$1.13▼$6.47Volume198,453 shsAverage Volume596,399 shsMarket Capitalization$51.59 millionP/E RatioN/ADividend YieldN/APrice Target$6.00Consensus RatingBuy Company OverviewLAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients. Its lead clinical-stage candidates are LAVA-1207 that is in Phase 1/2a clinical trial for metastatic castration-resistant prostate cancer. The company is developing other Gammabody drug candidates, which include LAVA-1223, which targets the epidermal growth factor receptor (EGFR) for the treatment of selected solid tumors, as well as LAVA-1266 which are preclinical candidates for the treatment of various hematologic malignancies. LAVA Therapeutics N.V. has a research collaboration and license agreement with Janssen Biotech, Inc. for the potential discovery and development of multi-specific antibody products that are directed to a specified target in various fields of use; and a collaboration with Merck & Co., Inc. to evaluate anti-PD-1 therapy KEYTRUDA in combination with LAVA-1207. LAVA Therapeutics N.V. was incorporated in 2016 and is headquartered in Utrecht, the Netherlands.Read More… Election warning coming true… (Ad)If you missed it, my emergency election broadcast is now available - watch it before it's too late.Click here to watch it now. LAVA Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks64th Percentile Overall ScoreLVTX MarketRank™: LAVA Therapeutics scored higher than 64% of companies evaluated by MarketBeat, and ranked 431st out of 997 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingLAVA Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageLAVA Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about LAVA Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for LAVA Therapeutics are expected to decrease in the coming year, from ($1.28) to ($1.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of LAVA Therapeutics is -2.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of LAVA Therapeutics is -2.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLAVA Therapeutics has a P/B Ratio of 0.60. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about LAVA Therapeutics' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.02% of the float of LAVA Therapeutics has been sold short.Short Interest Ratio / Days to CoverLAVA Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in LAVA Therapeutics has recently decreased by 75.51%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldLAVA Therapeutics does not currently pay a dividend.Dividend GrowthLAVA Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.02% of the float of LAVA Therapeutics has been sold short.Short Interest Ratio / Days to CoverLAVA Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in LAVA Therapeutics has recently decreased by 75.51%, indicating that investor sentiment is improving significantly. News and Social Media3.6 / 5News Sentiment1.43 News SentimentLAVA Therapeutics has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for LAVA Therapeutics this week, compared to 0 articles on an average week.Search InterestOnly 1 people have searched for LVTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows2 people have added LAVA Therapeutics to their MarketBeat watchlist in the last 30 days. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, LAVA Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.79% of the stock of LAVA Therapeutics is held by insiders.Read more about LAVA Therapeutics' insider trading history. Receive LVTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for LAVA Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address LVTX Stock News Headlines3 Healthcare Stocks Analysts Expect to Rally Over 50%September 25, 2024 | stocknews.comLAVA Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 3, 2024 | globenewswire.comElection warning coming true… If you missed it, my emergency election broadcast is now available - watch it before it's too late.October 29, 2024 | Porter & Company (Ad)LAVA Therapeutics: Promising Clinical Trials and Strategic Partnerships Bolster Buy RatingAugust 22, 2024 | markets.businessinsider.comBuy Rating Affirmed: LAVA Therapeutics’ Financial Stability and Promising Clinical PipelineAugust 21, 2024 | markets.businessinsider.comLAVA Reports Second Quarter 2024 Financial Results and Business UpdateAugust 20, 2024 | globenewswire.com4 Stocks Under $5 To Buy NowAugust 8, 2024 | 247wallst.comLAVA Therapeutics to Participate in the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual ConferenceJune 20, 2024 | globenewswire.comSee More Headlines LVTX Stock Analysis - Frequently Asked Questions How have LVTX shares performed this year? LAVA Therapeutics' stock was trading at $1.58 at the beginning of 2024. Since then, LVTX stock has increased by 28.8% and is now trading at $2.0350. View the best growth stocks for 2024 here. How were LAVA Therapeutics' earnings last quarter? LAVA Therapeutics (NASDAQ:LVTX) posted its earnings results on Tuesday, August, 20th. The company reported ($0.31) earnings per share for the quarter, topping the consensus estimate of ($0.36) by $0.05. LAVA Therapeutics had a negative net margin of 228.02% and a negative trailing twelve-month return on equity of 48.53%. When did LAVA Therapeutics IPO? LAVA Therapeutics (LVTX) raised $100 million in an initial public offering (IPO) on Thursday, March 25th 2021. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Jefferies and SVB Leerink acted as the underwriters for the IPO and Kempen & Co. was co-manager. Who are LAVA Therapeutics' major shareholders? Top institutional investors of LAVA Therapeutics include Pathway Financial Advisors LLC (0.40%). How do I buy shares of LAVA Therapeutics? Shares of LVTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of LAVA Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that LAVA Therapeutics investors own include Broadcom (AVGO), NVIDIA (NVDA), Adobe (ADBE), Arista Networks (ANET), New Oriental Education & Technology Group (EDU), ServiceNow (NOW) and AppLovin (APP). Company Calendar Last Earnings8/20/2024Today10/28/2024Next Earnings (Estimated)11/21/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:LVTX CUSIPN/A CIK1840748 Webwww.lavatherapeutics.com Phone31-85-016-3100FaxN/AEmployees60Year FoundedN/APrice Target and Rating Average Stock Price Target$6.00 High Stock Price Target$6.00 Low Stock Price Target$6.00 Potential Upside/Downside+194.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.08) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-41,970,000.00 Net Margins-228.02% Pretax Margin-323.30% Return on Equity-48.53% Return on Assets-23.94% Debt Debt-to-Equity Ratio0.01 Current Ratio6.39 Quick Ratio6.39 Sales & Book Value Annual Sales$7.40 million Price / Sales6.97 Cash FlowN/A Price / Cash FlowN/A Book Value$3.39 per share Price / Book0.60Miscellaneous Outstanding Shares25,350,000Free FloatN/AMarket Cap$51.59 million OptionableOptionable Beta0.51 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for November 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report This page (NASDAQ:LVTX) was last updated on 10/29/2024 by MarketBeat.com Staff From Our Partnerstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | SponsoredElon Musk Drops Stunning Bombshell?Elon Musk just dropped a BOMBSHELL that could send shockwaves throughout the tech industry… While deliverin...Paradigm Press | SponsoredTrump or Kamala? It may come down to this strange twist…Could this be the key to America's second coming? A strange resurrection born in the hollers of Appalachia? ...Porter & Company | SponsoredGold at $2,600... But This Stock Gives You More for Under $20Gold just soared over $2,600 an ounce. But what if I told you there's a way to get exposure to MORE than an...Monument Traders Alliance | Sponsored625,000% GainThe recent pullback in the crypto markets has left many investors in full-on panic mode, convinced the bull ru...Crypto Swap Profits | Sponsored“Buffett Indicator” Predicts 62% Stock Market CrashThe last time the "Buffett Indicator" flashed this red was in 2000 - right before the market crashed 50%.Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding LAVA Therapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share LAVA Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.